4D Pharma Plc, which is developing live biotherapeutic products for cancer, has appointed John Beck as chief financial officer and a member of the management team. Live biotherapeutics are a class of drug derived from the microbiome. Mr Beck joins the company from Ritter Pharmaceuticals where he was CFO and oversaw the company’s merger with Qualigen Therapeutics Inc, an oncology drug developer. He was also CFO of Ardea Biosciences where he completed a $1.2 billion merger with AstraZeneca Plc in 2012.
Mr Beck holds a bachelor’s degree in accounting from the University of Washington, Seattle and a degree in theology from a Seattle area seminary, US.
4D Pharma announced the appointment on 1 March 2021.
Copyright 2021 Evernow Publishing Ltd